Stacy Loeb researcher
Loeb, Stacy
VIAF ID: 308728229 (Personal)
Permalink: http://viaf.org/viaf/308728229
Preferred Forms
-
100 1 _
‡a
Loeb, Stacy
-
100 0 _
‡a
Stacy Loeb
‡c
researcher
4xx's: Alternate Name Forms (3)
Works
| Title | Sources |
|---|---|
| Prostate cancer: utility of the risk indicator model in screening |
|
| The Prostate Health Index: a new test for the detection of prostate cancer |
|
| Prostate Health Index (PHI): Golden Bullet or Just Another Prostate Cancer Marker? |
|
| Prostate specific antigen assay standardization bias could affect clinical decision making. |
|
| Prostate Specific Antigen at the Initial Diagnosis of Metastasis to Bone in Patients After Radical Prostatectomy |
|
| Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program |
|
| PSA and beyond: the past, present, and future of investigative biomarkers for prostate cancer. |
|
| PSA velocity is associated with gleason score in radical prostatectomy specimen: marker for prostate cancer aggressiveness |
|
| Public online reporting from a nationwide population-based clinical prostate cancer register. |
|
| Qualitative study on decision-making by prostate cancer physicians during active surveillance. |
|
| Qualitative Twitter analysis of participants, tweet strategies, and tweet content at a major urologic conference |
|
| Quantifying downstream impact of inappropriate staging imaging in a cohort of veterans with low- and intermediate-risk incident prostate cancer |
|
| Radical retropubic prostatectomy: comparison of the open and robotic approaches for treatment of prostate cancer. |
|
| Randomized trials of selenium, vitamin e, or vitamin C for prostate cancer prevention |
|
| A rare 8q24 single nucleotide polymorphism (SNP) predisposes North American men to prostate cancer and possibly more aggressive disease |
|
| Re: Editorial Comment on Use of Phosphodiesterase Type 5 Inhibitors for Erectile Dysfunction and Risk of Malignant Melanoma: D. F. Penson J Urol 2015;194:1710-1711. |
|
| Reducing blood loss in open radical retropubic prostatectomy with prophylactic periprostatic sutures |
|
| Regional variation in total cost per radical prostatectomy in the healthcare cost and utilization project nationwide inpatient sample database |
|
| Relationship of prostate-specific antigen velocity to histologic findings in a prostate cancer screening program |
|
| Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. |
|
| Risk factors, prevention and early detection of prostate cancer |
|
| Risk of malignant melanoma in men with prostate cancer: Nationwide, population-based cohort study |
|
| Risk of Prostate Cancer for Young Men With a Prostate Specific Antigen Less Than Their Age Specific Median |
|
| The role of high-intensity focused ultrasound in prostate cancer. |
|
| The role of prostate cancer biomarkers in undiagnosed men. |
|
| Screening for familial and hereditary prostate cancer |
|
| Shift from protocol-based to personalized medicine in active surveillance: beginning of a new era. |
|
| Should prostate specific antigen be adjusted for body mass index? Data from the Baltimore Longitudinal Study of Aging |
|
| Significance of preoperative PSA velocity in men with low serum PSA and normal DRE. |
|
| Small bowel obstruction and abdominal pain after robotic versus open radical prostatectomy |
|
| Social Media Coverage of Scientific Articles Immediately After Publication Predicts Subsequent Citations - #SoME_Impact Score: Observational Analysis |
|
| Social media makes global urology meetings truly global. : The influence of Twitter. |
|
| Social media offers unprecedented opportunities for vibrant exchange of professional ideas across continents |
|
| Standard and Targeted Biopsy During Follow-up for Active Surveillance |
|
| Survival results in patients with screen-detected prostate cancer versus physician-referred patients treated with radical prostatectomy: early results |
|
| Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system |
|
| Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer. |
|
| Time to replace prostate-specific antigen (PSA) with the Prostate Health Index (PHI)? Yet more evidence that the PHI consistently outperforms PSA across diverse populations. |
|
| "To measure is to know. If you cannot measure it, you cannot improve it": statistical modeling cannot compensate for unmeasured bias |
|
| Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression |
|
| Treatment outcomes of radical prostatectomy in potential candidates for 3 published active surveillance protocols |
|
| Tumor Characteristics of Carriers and Noncarriers of the deCODE 8q24 Prostate Cancer Susceptibility Alleles |
|
| Tweet this: how advocacy for breast and prostate cancers stacks up on social media. |
|
| Twitter Activity Associated With U.S. News and World Report Reputation Scores for Urology Departments |
|
| Twitter and academic Urology in the United States and Canada: a comprehensive assessment of the Twitterverse in 2019 |
|
| Twitter-based Prostate Cancer Journal Club (#ProstateJC) Promotes Multidisciplinary Global Scientific Discussion and Research Dissemination |
|
| Twitter response to the United States Preventive Services Task Force recommendations against screening with prostate-specific antigen. |
|
| Understanding the Composition of a Successful Tweet in Urology |
|
| Undertreatment of Men in Their Seventies with High-risk Nonmetastatic Prostate Cancer |
|
| United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015 |
|
| Unusual Presentation of a Mullerian Remnant in an Infant with Recurrent Epididymo-orchitis |
|
| Update on the Urology Tag Ontology: Standardized Hashtags for Social Media in Urology |
|
| Updates in the care and management of prostate cancer: highlights from the 2013 prostate cancer world congress, august 6-10, 2013, melbourne, australia |
|
| Upper limit of cancer extent on biopsy defining very low-risk prostate cancer |
|
| Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden |
|
| The Urology Care Foundation - trusted online resources in an era of misinformation |
|
| Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years |
|
| Use of BioGlue in laparoscopic partial nephrectomy |
|
| Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015 |
|
| Use of Empiric Antibiotics in the Setting of an Increased Prostate Specific Antigen |
|
| Use of Prostate-Specific Antigen Velocity to Follow Up Patients with Isolated High-Grade Prostatic Intraepithelial Neoplasia on Prostate Biopsy |
|
| Use of social media in urology: data from the American Urological Association (AUA). |
|
| The use of Twitter to facilitate sharing of clinical expertise in urology. |
|
| Using data from an online health community to examine the impact of prostate cancer on sleep |
|
| The vanishing prostate cancer phenomenon |
|
| What is the prognostic impact of positive surgical margins in surgically treated prostate cancer? |
|
| What is the role of digital rectal examination in men undergoing serial screening of serum PSA levels? |
|
| What is the true mortality benefit of prostate-specific antigen screening? |
|
| What to do with an abnormal PSA test. |
|
| When is a Negative Prostate Biopsy Really Negative? Repeat Biopsies in Detection and Active Surveillance. |
|
| Whom to Biopsy: Prediagnostic Risk Stratification with Biomarkers, Nomograms, and Risk Calculators. |
|
| Will Changes to Prostate Cancer Screening Guidelines Preserve Benefits and Reduce Harm? |
|
| Words of wisdom. Re: Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, represe |
|
